Seattle Children’s Opens CD22 CAR T-Cell Immunotherapy Trial for Children and Youthfull Adults Whose Leukemia Escapes CD19 CAR T-Cell Therapy

After eyeing promising results in phase one of the Pediatric Leukemia Adoptive Therapy (PLAT-02) trial with ninety three percent of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) achieving accomplish initial remission, researchers at Seattle Children’s are continuing their quest to improve the experimental therapy and reduce the rate of relapse, which is about fifty percent. Read more